AbbVie (ABBV) highlighted its strategic shift beyond HUMIRA at the Morgan Stanley Healthcare Conference on September 15, 2026, projecting a $10 billion higher peak revenue than the drug’s previous maximum. The biopharma giant announced a $28 billion boost in ex-HUMIRA growth, countering $18 billion in HUMIRA erosion, with revenue reaching $64.39 billion over the past year—a 10% annual growth rate. The company’s market capitalization stood at $462.56 billion, with shares trading at $262.81, near their 52-week high of $267.47, following a prior reference of $257.12 USD. AbbVie’s gross profit margin remained nearly 73%, and its trailing P/E ratio was 74, reflecting a 24% return over the past year. The company has sustained 14 consecutive years of dividend increases, yielding 2.64% annually.
The focus at the conference centered on AbbVie’s pipeline, which includes three franchises with over $5 billion in peak potential: neuroscience, migraine, and immunology. Key assets under development include SKYRIZI, a subcutaneously administered induction therapy for atopic dermatitis, with early 2030 launch targets pending formulary review. Zumilokibart, acquired via the Apogee deal, is also set for early 2030 approval. Clinical data for SKYRIZI demonstrated a 45% improvement in endoscopic response and clinical remission in treatment-naive patients. RINVOQ, meanwhile, secured patent protection through 2037 for atopic dermatitis.
In dermatology, AbbVie is targeting four additional indications for RINVOQ: giant cell arteritis (GCA), lupus, hidradenitis suppurativa, vitiligo, and alopecia. Phase IIa combination trials with alpha 4 beta 7, TL1A, and TREM1 inhibitors showed doubled endoscopic remission versus SKYRIZI alone. Zumilokibart’s phase IIb data held up globally, with EASI-100 results numerically comparable to RINVOQ’s efficacy. The atopic dermatitis patient population is estimated at three times that of psoriasis, with only a third currently treated.
Neuroscience remains a cornerstone, with Vyalev expected to achieve blockbuster status in 2026. Tavapadon demonstrated 85 weeks of control without increasing oral levodopa and carbidopa, alongside minimal somnolence or impulsive control disorders. AbbVie’s Aliada partnership involves an A-beta agent with blood-brain barrier penetration in phase I-B, targeting monthly subcutaneous dosing. ADARx’s siRNA for tau with blood-brain barrier crossing technology is also advancing.
Oncology highlights included Etentamig, a next-generation BCMA T-cell engager for multiple myeloma, which showed high efficacy. A data monitoring committee recommended early termination due to its efficacy, featuring once-monthly dosing, grade 3-plus infections under 30%, and lower cytokine release syndrome rates than competitors. AbbVie has completed around 30 to 40 transactions over the past 2.5 years, predominantly early-stage deals.
Rob Michael, Chairman and CEO, emphasized the ex-HUMIRA growth platform’s offsetting HUMIRA erosion, particularly in immunology and neuroscience. Jeff Stewart, Executive Vice President of Commercial Affairs, noted the underserved atopic dermatitis market, with only a third of the patient population currently treated. The company’s robust pipeline underscores its ambition to diversify beyond HUMIRA, positioning AbbVie for sustained growth in emerging therapeutic areas.
